Referencias

Barnes, T. R., & Paton, C. (2011). Antipsychotic Polypharmacy in Schizophrenia. CNS Drugs,
25(5), 383-399.
Canfrn-Duque, A., Barrio, L., Lerma, M., Pea, G. D., Serna, J., Pastor, O., . . . Busto, R.
(2016). First-Generation Antipsychotic Haloperidol Alters the Functionality of the Late
Endosomal/Lysosomal Compartment in Vitro. IJMS International Journal of Molecular
Sciences, 17(3), 404.
Crespo-Facorro, Benedicto, Roco Prez-Iglesias, Mariluz Ramirez-Bonilla, Obdulia MartnezGarca, Javier Llorca, and Jos Luis Vzquez-Barquero. (2006). A Practical Clinical
Trial Comparing Haloperidol, Risperidone, and Olanzapine for the Acute Treatment of
First-Episode Nonaffective Psychosis. J. Clin. Psychiatry The Journal of Clinical
Psychiatry 67.10 1511-521.
Dold, M., Samara, M. T., Li, C., Tardy, M., & Leucht, S. (2015). Haloperidol versus firstgeneration antipsychotics for the treatment of schizophrenia and other psychotic
disorders. Cochrane Database of Systematic Reviews Reviews.
doi:10.1002/14651858.cd009831.pub2
Favretto, D., Stocchero, G., Nalesso, A., Vogliardi, S., Boscolo-Berto, R., Montisci, M., &
Ferrara, S. D. (2013). Monitoring Haloperidol Exposure in Body Fluids and Hair of
Children by Liquid ChromatographyHigh-Resolution Mass Spectrometry. Therapeutic
Drug Monitoring, 35(4), 493-501. doi:10.1097/ftd.0b013e3182892d11
Folweiler, K., Bondi, C. O., Ogunsanya, E., Laporte, M., Leary, J., Radabaugh, H., . . . Kline,
A. E. (2016). Combining the antipsychotic drug haloperidol and environmental
enrichment after traumatic brain injury is a double-edged sword. Journal of
Neurotrauma. doi:10.1089/neu.2016.4417
Handley, S., Patel, M. X., & Flanagan, R. J. (2016). Antipsychotic-related fatal poisoning,
England and Wales, 19932013: Impact of the withdrawal of thioridazine. Clinical
Toxicology, 1-10. doi:10.3109/15563650.2016.1164861
Kroken, R. A., Johnsen, E., Ruud, T., Wentzel-Larsen, T., & Jrgensen, H. A. (2009).
Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a
cross-sectional national study. BMC Psychiatry, 9(1), 24. doi:10.1186/1471-244x-9-24
Mori, T., Iwase, Y., Murata, A., Iwata, N., & Suzuki, T. (2016). Brain site- and transmitterdependent actions of methamphetamine, morphine and antipsychotics. Behavioural
Brain Research, 306, 64-70. doi:10.1016/j.bbr.2016.03.024
Porcelli, S., Crisafulli, C., Calabr, M., Serretti, A., & Rujescu, D. (2016). Possible biomarkers
modulating haloperidol efficacy and/or tolerability. Pharmacogenomics.

Suzuki, T., Remington, G., Arenovich, T., Uchida, H., Agid, O., Graff-Guerrero, A., & Mamo,
D. C. (2011). Time course of improvement with antipsychotic medication in treatmentresistant schizophrenia. The British Journal of Psychiatry, 199(4), 275-280.
Tandon, R. (2011). Antipsychotics in the Treatment of Schizophrenia. J. Clin. Psychiatry The
Journal of Clinical Psychiatry, 72(Suppl 1).
Valevski, A., Gilat, Y., Olfson, M., Benaroya-Milshtein, N., & Weizman, A. (2012).
Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia
patients. International Clinical Psychopharmacology, 27(3), 159-164.
Vitiello, B., et al., (2009). Antipsychotics in children and adolescents: Increasing use, evidence
for efficacy and safety concerns, Eur. Neuropsychopharmacol.